Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Regen BioPharma (RGBP) Net Margin (2016 - 2025)

Regen BioPharma (RGBP) has disclosed Net Margin for 11 consecutive years, with 964.31% as the latest value for Q3 2025.

  • On a quarterly basis, Net Margin fell 50824.0% to 964.31% in Q3 2025 year-over-year; TTM through Dec 2025 was 427.68%, a 16694.0% increase, with the full-year FY2025 number at 538.76%, down 25627.0% from a year prior.
  • Net Margin was 964.31% for Q3 2025 at Regen BioPharma, down from 283.23% in the prior quarter.
  • In the past five years, Net Margin ranged from a high of 194720.47% in Q2 2022 to a low of 114926.74% in Q1 2022.
  • A 5-year average of 3888.24% and a median of 189.45% in 2023 define the central range for Net Margin.
  • Peak YoY movement for Net Margin: soared 22036286bps in 2022, then plummeted -19488846bps in 2023.
  • Regen BioPharma's Net Margin stood at 7557.09% in 2021, then crashed by -39bps to 4577.87% in 2022, then plummeted by -105bps to 245.34% in 2023, then plummeted by -256bps to 872.57% in 2024, then dropped by -11bps to 964.31% in 2025.
  • Per Business Quant, the three most recent readings for RGBP's Net Margin are 964.31% (Q3 2025), 283.23% (Q2 2025), and 32.77% (Q1 2025).